Psychedelic therapy: a roadmap for wider acceptance and utilization.

@article{Marks2021PsychedelicTA,
  title={Psychedelic therapy: a roadmap for wider acceptance and utilization.},
  author={Mason Marks and Ivan Glenn Cohen},
  journal={Nature medicine},
  year={2021}
}
Physical Disability and Psychedelic Therapies: An Agenda for Inclusive Research and Practice
TLDR
The need for extensive disability awareness training for those facilitating psychedelic therapies and the encouragement of psychedelic researchers and therapists to exercise cultural humility toward individuals with physical and sensory disabilities are emphasized.
Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials.
RATIONALE Psychedelic research continues to garner significant public and scientific interest with a growing number of clinical studies examining a wide range of conditions and disorders. However,
A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders
TLDR
Methylenedioxymethamphetamine and psilocybin may show promise in highly selected populations when administered in closely supervised settings and with intensive support, and both agents were well tolerated in supervised trials.
Great Expectations: Recommendations for improving the methodological rigor of psychedelic clinical trials
Rationale: Psychedelic research continues to garner significant public and scientific interest with a growing number of clinical studies examining a wide range of conditions and disorders. However,

References

SHOWING 1-8 OF 8 REFERENCES
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder
This randomized clinical trial examines the efficacy of psilocybin as an adjunct to psychotherapy and other treatments for major depressive disorder.
Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer
Background: A recently published randomized controlled trial compared single-dose psilocybin with single-dose niacin in conjunction with psychotherapy in participants with cancer-related psychiatric
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials
TLDR
MDMA-assisted psychotherapy was efficacious and well tolerated in a large sample of adults with PTSD and supported expansion into phase 3 trials and led to FDA granting Breakthrough Therapy designation for this promising treatment.
Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature
TLDR
Inclusion of minorities in futures studies and improved recruitment strategies are necessary to better understand the efficacy of psychedelic-assisted psychotherapy in people of color and provide all with equal opportunities for involvement in this potentially promising treatment paradigm.
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
TLDR
High-dose psilocybin produced large decreases in clinician- and self-rated measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety.
Harm potential of magic mushroom use: a review.
Psilocybin for treating substance use disorders?
TLDR
A summary of (human) studies on the putative therapeutic effects of psilocybin is provided, and the receptor systems, brain regions and cognitive and emotional processes mediating p silocybin’s effects are discussed.